Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2569 • ACR Convergence 2025
Performance of the PREVENT Heart Failure General Population Risk Score in Patients with Rheumatoid Arthritis
Ilana Usiskin¹, Katherine Zhong², Ying Qi³, Lauren rusnak¹, Andrew Cagan¹, Yumeko Kawano¹, Tianrun Cai¹, Daniel Solomon⁴, Jennifer Ho⁵, Brittany Weber⁶ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Short Hills, NJ, ³Brigham and Women’s Hospital, Boston, ⁴Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of heart failure (HF) compared to the general population, and HF with preserved ejection fraction…
Abstract Number: 2282 • ACR Convergence 2025
Effect of Online Continuing Education on Advancing Care for Rheumatoid Arthritis: A Real-World Outcome Analysis
Nimish Mehta¹, Katie Lucero², Freddy Green³ and Karen Badal⁴, ¹Medscape, Three Bridges, NJ, ²Medscape, Newark, ³Medscape, London, United Kingdom, ⁴Medscape, New York, NY
Background/Purpose: In recent years, an increasing number of cytokines and their function in the pathophysiology of immunologic conditions have been identified, leading to the development…
Abstract Number: 2264 • ACR Convergence 2025
Male Sex and Obesity Are Risk Factors for Sarcopenia in RA: Korea National Health and Nutrition Survey 2008–2011
Yoon-Jeong Oh¹, Jin-Wuk Hur² and Chang-Nam Son³, ¹Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu, Republic of Korea, ²Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Republic of Korea, ³UIJEONGBU EULJI MEDICAL CENTER, EULJI UNIVERSITY, UIJEONGBU, Republic of Korea
Background/Purpose: Sarcopenia is a medical condition characterized by the progressive loss of skeletal muscle mass, strength, and function. It is primarily associated with aging, but…
Abstract Number: 2247 • ACR Convergence 2025
A Pilot Study to identify novel autoantibody biomarkers in Rheumatoid Arthritis (RA) patients using Immunome Protein Array
Margaret Ma¹, Peter Cheung¹, ee tzun koh², janique peyper³, bermet abylova³ and Khai Pang Leong², ¹National University Hospital, Singapore, Singapore, ²Tan Tock Seng Hospital, Singapore, Singapore, ³Standard BioTools, Singapore, Singapore
Background/Purpose: RA is a heterogenous condition with variable outcomes. The identification of novel autoantibodies and autoantibody signatures could help us identify potential diagnostic and prognostic…
Abstract Number: 2232 • ACR Convergence 2025
Risk factors for hospitalizations in a large, contemporary rheumatoid arthritis patient cohort
Argyro Lazarini¹, Konstantinos Thomas², EVRIPIDIS KALTSONOUDIS³, Paraskevi V Voulgari⁴, Alexandros Drosos⁵, Argyro Repa⁶, Ainour Molla ismail Sali⁶, Prodromos Sidiropoulos⁶, Kalliopi Fragkiadaki¹, Maria Tektonidou⁷, Petros Sfikakis⁸, Panagiota Tsatsani⁹, Sousana Gazi⁹, Evangelia Argyriou¹⁰, Kyriaki Boki¹⁰, Pelagia Katsimpri¹, Dimitrios Boumpas¹, Gerasimos Evangelatos¹¹, Alexios Iliopoulos¹², Konstantina Karagianni¹³, Lazaros Sakkas¹³, Konstantinos Melissaropoulos¹⁴, Panagiotis Georgiou¹⁴, Eleftheria Grika¹, PANAYIOTIS VLACHOYIANNOPOULOS¹, Theodoros Dimitroulas¹⁵, Alexandros Garyfallos¹⁶, Konstantinos Georganas¹⁷, Periklis Vounotrypidis¹⁸, Konstantinos Ntellis¹⁹, Georgios Kitas²⁰ and Dimitrios Vassilopoulos²¹, ¹Joint Rheumatology Program, University of Athens Medical School, Athens, Greece, ²Joint Rheumatology Program, University of Athens Medical School, Athens, Greece, ³Rheumatology Clinic, University of Ioannina, IOANNINA, Ioannina, Greece, ⁴Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Ioannina, Greece, ⁵Rheumatology Clinic, University of Ioannina, Ioannina, Greece, ⁶Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece, ⁷National and Kapodistrian University of Athens, Athens, Greece, ⁸NKUA - SCHOOL OF MEDICINE, Athens, Greece, ⁹Rheumatology Unit, KAT Hospital, Athens, Greece, ¹⁰Rheumatology Unit, Sismanoglio Hospital, Athens, Greece, ¹¹Third Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Sotiria Hospital, Athens, Attiki, Greece, ¹²⁴¹⁷ Army Share Fund Hospital (NIMTS), Department of Rheumatology, Athens, Greece, ZOGRAFOU, Greece, ¹³Department of Rheumatology, University of Thessaly, Larissa, Greece, ¹⁴Rheumatology Unit, Agios Andreas Hospital, Patras, Greece, ¹⁵Hippokration University Hospital, Medical School, Aristotle University of Thessaloniki, Fourth Department of Internal Medicine, Thessaloniki, Greece, Thessaloniki, Greece, ¹⁶⁴th Department of Medicine, Aristotle University, Thessaloniki, Greece, ¹⁷Private office, Athens, ¹⁸Private office, Thessaloniki, Greece, ¹⁹Private office, Kalamata, Greece, ²⁰Hygeia Hospital, Athens, Greece, ²¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, General Hospital of Athens “Hippokration”, Clinical Immunology-Rheumatology Unit, ²nd Department of Medicine and Laboratory, Athens, Greece, Athens, Greece
Background/Purpose: There are limited data regarding the recent trends and risk factors for hospitalization in patients with rheumatoid arthritis (RA). Our aim was to estimate…
Abstract Number: 2016 • ACR Convergence 2025
Effectiveness of Nintedanib combined with different DMARDs in joint and pulmonary domains of Rheumatoid Arthritis – Interstitial Lung Disease. National multicenter study of 74 patients
Ana Serrano-Combarro¹, Jesús Loarce², Belén Atienza-mateo³, Nuria Vegas Revenga⁴, Maria Martín López⁵, Santos Castañeda⁶, Rafael B. Melero-González⁷, Natalia Mena Vázquez⁸, Carmen Carrasco-Cubero⁹, Carolina Diez-Morrondo¹⁰, David Castro-Corredor¹¹, Tomas Ramon Vazquez Rodriguez¹², Andrea García-Valle¹³, Gema Bonilla¹⁴, Marina Rodríguez Lopez¹⁵, Ignacio Braña¹⁶, Pablo Andujar¹⁷, Sara Maria Rojas Herrera¹⁸, Juan Camilo Sarmiento-Monroy¹⁹, Diego Ferrer²⁰, Ivan Ferraz Amaro²¹ and Ricardo Blanco²², ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²Ramón y Cajal University Hospital, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, ⁴Galdakao- Usansolo University Hospital, Galdakao, Spain, ⁵Hospital ¹² de Octubre, Madrid, Spain, ⁶Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁷COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁸Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ⁹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹⁰Complejo Asistencial Universitario de León, León, Spain, ¹¹Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹²Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain, ¹³Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ¹⁴Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹⁵Complejo Hospitalario Universitario de Santiago, Santiago, Spain, ¹⁶Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁷Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁸Hospital de Mérida, Rheumatology, Badajoz, Badajoz, Spain, ¹⁹Hospital Clínic Barcelona, Barcelona, Spain, ²⁰Department of Pulmonology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²¹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA) and its management remains a challenge. Approximately one third of the patients…
Abstract Number: 1920 • ACR Convergence 2025
Lung Cancer Screening with Rheumatoid Arthritis: A Retrospective Claims Analysis
Angeles Lopez-Olivio¹, Zhigang Duan², Huifang Lu³, Edwin J. Ostrin², Robert J. Volk², Ying Xu², Sharon H. Giordano⁴ and Hui Zhao⁴, ¹The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³UT MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas MD Anderson Cancer Center, Houston
Background/Purpose: Patients with rheumatoid arthritis (RA) are at elevated risk for lung cancer. Lung cancer screening (LCS) with low-dose computed tomography (LDCT) is recommended for…
Abstract Number: 1746 • ACR Convergence 2025
Inflammatory- and Fibrosis-Related Biomarkers and Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk
Bryant England¹, Tate Johnson¹, Michael Duryee¹, Halie Frideres², Katherine Wysham³, Grant Cannon⁴, Gary Kunkel⁵, Dana Ascherman⁶, John Richards⁷, Paul Monach⁸, Gail Kerr⁹, Andreas Reimold¹⁰, Joshua Baker¹¹, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC Department of Rheumatology, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Dallas VA Medical Center, Dallas, TX, ¹¹University of Pennsylvania, Philadelphia, PA
Background/Purpose: There exists a need to identify informative peripheral blood biomarkers for RA-interstitial lung disease (RA-ILD) and elucidate the pathophysiological processes driving RA-ILD onset. Several…
Abstract Number: 1661 • ACR Convergence 2025
Artificial Intelligence applied to Patient Reported Outcomes and Passive Physiologic Sensor Data can Accurately Classify Low Disease Activity in Rheumatoid Arthritis Patients
Jeffrey Curtis¹, Yujie Su², sam Barskiy³, Emily Holladay³, Shilpa Venkatachalam⁴, David Curtis⁵, Tapan Mehta³ and Fenglong Xie⁶, ¹Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Global Healthy Living Foundation, New York, NY, ⁵Global Healthy Living Foundation, Meriden, ⁶The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Remote therapeutic monitoring (RTM) and remote physiologic monitoring (RPM) programs have the potential to capture data between clinical visits and provide information back to…
Abstract Number: 1369 • ACR Convergence 2025
Impact of SGLT2 Inhibitors and GLP-1 Agonists on RA Flares in Patients on DMARD Therapy: A Retrospective Study
Shreya Sakthivel¹, Mitch Karpman², Liam Oland³ and Amer Aldamouk⁴, ¹Anne Arundel Medical Center, Washington DC, DC, ²Anne Arundel Medical Center, Annapolis, ³Saba University School of Medicine, Annapolis, ⁴Anne Arundel Medical Center, Washington, DC
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease driven by T- and B-cell activation and pro-inflammatory cytokines such as TNF-α and IL-6 and is…
Abstract Number: 1351 • ACR Convergence 2025
Are Glucocorticoids Associated with Worse Overall Survival among Rheumatoid Arthritis Patients Treated with Immune Checkpoint Inhibitors? The Confounding Effect of Dexamethasone
Deanna Jannat-Khah¹, Jeffrey Curtis², Fenglong Xie³, Ashish Saxena⁴ and Anne R. Bass¹, ¹Hospital For Special Surgery, New York, NY, ²Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, New York
Background/Purpose: Previous studies suggest that glucocorticoids are associated with worse survival in patients receiving immune checkpoint inhibitors (ICI). This is an important issue for Rheumatoid…
Abstract Number: 1334 • ACR Convergence 2025
Cardiac Biomarkers and Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort
manon lesturgie¹, Fiona Oudart¹, Anne Cauvet², Virginie Gonzalez², Bruno Fautrel³, Arnaud Constantin⁴, Nathalie Rincheval⁵, Yannick Allanore⁶ and Jérôme Avouac⁷, ¹INSERM U¹⁰¹⁶, Paris, France, ²INSERMU¹⁰¹⁶, Paris, France, ³Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ⁴Hôpital Pierre-Paul Riquet, CHU Purpan, Toulouse, France, ⁵Institut de Recherche Clinique EA²⁴¹⁵, Université de Montpellier, Département de Statistiques, Montpellier, France, ⁶Université Paris Cité, Paris, France, ⁷Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Patients with rheumatoid arthritis (RA) experience premature mortality, largely due to cardiovascular (CV) disease. The increased CV risk is due to both the underlying…
Abstract Number: 1318 • ACR Convergence 2025
Diagnostic Delay in Rheumatoid Arthritis and its Impact on Radiographic Outcomes: A Systematic Review and Meta-analysis of 100,066 Patients
Mohamed Abdelsalam¹, Menat Alla Ayman Ali Mahdy², Bassant Elaraby Elsayed Badwy², Maryam Lasheen³, Omar Sameh Nabil El Sedafy¹, Hadeer Hafez⁴ and Mohamed Reda Awad⁵, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ³Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Timely diagnosis is the cornerstone of effective rheumatoid arthritis (RA) management, with early treatment shown to significantly improve outcomes through a treat-to-target strategy. While…
Abstract Number: 1249 • ACR Convergence 2025
Association between Positive Emotions and Physical Function in Early Rheumatoid Arthritis Patients
Burcu Aydemir¹, Jing Song², Lutfiyya muhammad¹, Dorothy Dunlop³, Rowland Chang¹, Wendy Marder⁴, Kevin Deane⁵, Clifton Bingham⁶, Vivian Bykerk⁷, Robert Edwards⁸, Judy Moskowitz¹ and Yvonne Lee⁹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Worthington, MN, ³Northwestern University Feinberg School of Medicine, Chicago, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁶Johns Hopkins University, Baltimore, MD, ⁷Hospital For Special Surgery, New York, NY, ⁸Brigham and Women's Hospital & Harvard Medical School, Boston, MA, ⁹Northwestern University, Chicago, IL
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that can significantly impair physical function and quality of life. While physical symptoms such as joint…
Abstract Number: 1091 • ACR Convergence 2025
Safety Profile of ICIs in Patients with Rheumatoid Arthritis: Results from a Propensity Score-Matched Cohort Study
Betul Ibis¹, Furkan Bahar¹, Yu-Che Lee², Ko-Yun Chang³, Yu Chang⁴ and Cho-Han Chiang⁵, ¹Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²University at Buffalo, Buffalo, NY, ³National Jewish Health, Denver, CO, ⁴National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), ⁵Mount Auburn Hospital, Harvard Medical School, Cambridge
Background/Purpose: Immune-related adverse events (irAEs) are a significant concern for patients receiving immune checkpoint inhibitors (ICIs), particularly those with pre-existing rheumatoid arthritis (RA). Managing ICIs…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].